Cephalosporin Market Research Report Focusing on Leading Fortune Companies namely, Allergan Plc., Bristol-Myers Squibb Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Limited, Merck & Co. Inc., Novartis International AG, Pfizer Inc., and oth

The global cephalosporin market was valued at $3,136 million in 2016, and is projected to reach $4,980 million by 2023, growing at a CAGR of 6.8% from 2017 to 2023. Rise in incidence of infectious diseases, surge in R&D activities for discovery of combination drugs, and increase in funding for antibiotics development drive the growth in the global cephalosporin market. Based on regions, Asia-Pacific contributed the largest market share based on revenue in 2017, accounting for nearly three-fifths of the total share. This region would continue to dominate in terms of revenue during the forecast period.

Download Report Sample at: https://www.alliedmarketresearch.com/request-sample/3510

Growth Drivers and Industry Trends

Rise in incidence of infectious diseases, surge in R&D activities for discovery of combination drugs, and increase in funding for antibiotics development drive the growth in the global cephalosporin market. However, side effects related to cephalosporin and antibiotic resistance restrain the market growth. On the other hand, new opportunities from emerging nations create opportunities for the future.

Based on generation, the third-generation cephalosporin segment held the major position in 2017, contributing nearly two-fifths of the total share. This segment is expected to maintain its lead position throughout the forecast period. However, the fourth-generation cephalosporin segment would grow at the highest CAGR of 2.8% from 2018 to 2025. The research also analyzes first-generation, second-generation, and fifth-generation cephalosporin.

Segmentation Analysis of the Industry

Based on type, the branded segment contributed the highest market share, accounting for nearly three-fifths of the total share in 2017, and is expected to continue to dominate throughout the forecast period. This segment would register the highest growth rate, with a CAGR of 2.3% from 2018 to 2025. It is a lucrative segment and present numerous growth opportunities. The report also explores generic type of cephalosporin.

Asia-Pacific contributed the largest market share based on revenue in 2017, accounting for nearly three-fifths of the total share. This region would continue to dominate in terms of revenue during the forecast period. However, LAMEA is expected grow at the fastest CAGR of 4.2% during the forecast period, 2018–2025. The research also analyzes other regions including North America and Europe.

Industry Key Players

Leading market players active in the global cephalosporin market include Allergan Plc., F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Lupin Limited (Lupin Pharmaceuticals, Inc.), GlaxoSmithKline Plc, Novartis International AG, Merck & Co. Inc., Sanofi, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. They have adopted various strategies including partnerships, collaborations, mergers & acquisitions, and others to gain a strong position and sustain in the industry.

Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/3510

Table Of Content

Chapter: 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key Findings
3.2.1. Top investment pockets
3.3. Top winning strategies
3.3.1. Top Winning Strategies, by year, 2015-2018*
3.3.2. Top Winning Strategies, by development, 2015-2018* (%)
3.3.3. Top Winning Strategies, by company, 2015-2018*
3.3.4. Market Dynamics
3.3.5. Drivers
3.3.5.1. Surge in incidence of infectious diseases
3.3.5.2. Increase in R&D activities for the development of combination drugs
3.3.5.3. Rise in funding for the development of antibiotics
3.3.6. Restraints
3.3.6.1. Side effects associated with cephalosporin
3.3.6.2. Antibiotic resistance to cephalosporin
3.3.7. Opportunities
3.3.7.1. Lucrative opportunities in the emerging economies
3.4. Market Share Analysis, 2017
3.5. Porter’s Five Forces Analysis
3.6. Novel Molecules in Cephalosporin Market
3.6.1. Ceftazidime
3.6.2. Cefuroxime
3.7. Combination Therapies in Cephalosporin Market

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/Cephalosporin-market.html

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.